Generic Version of Promising AIDS Drug Could Cost Only $40

Researchers have calculated that a generic version of the AIDS drug Lenacapavir could cost as little as $40 per patient, a significant reduction from the current price of $40,000. Lenacapavir, developed by Gilead, has the potential to revolutionize the fight against AIDS and has shown a 100% success rate in preventing HIV transmission.

The drug, which only needs to be injected twice a year, could act like a vaccine and effectively stop the transmission of HIV. However, with the current price, most people cannot afford the treatment.

Researchers estimate that a generic version could be produced at a much lower cost based on raw material prices and conversations with generic manufacturers in China and India. Gilead is facing pressure to allow generic versions of Lenacapavir, with the UNAIDS director urging the company to make history and save lives.

Gilead states that it has been in discussions with governments and NGOs to ensure widespread access to Lenacapavir. While the drug is still awaiting clinical trial results for HIV prevention, it has the potential to provide an affordable and life-saving treatment option for the millions of people worldwide who currently lack access to effective HIV treatment.